A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p ...

A substantial proportion of U.S. children aged 6–17 with overweight or obesity exhibit borderline or abnormal cardiometabolic risk markers, including dyslipidemia, diabetes, and non-alcoholic ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP ...

A once-weekly subcutaneous injection of CT-388 achieved a statistically significant placebo-adjusted weight loss of 22.5% (p 54% of participants on the 24 mg dose achieved resolution of obesity (BMI C ...

The effect of obesity on brain health may depend not only on how much fat is in the body, but also on the areas of the body where fat is stored, according to a study published today in Radiology , the ...

The effect of obesity on brain health may depend not only on how much fat is in the body, but also on the areas of the body where fat is stored, according to a study published today in Radiology.

Tackling obesity can help patients 'gain life' and curb hundreds of associated health problems ...

The effect of obesity on brain health may depend not only on how much fat is in the body, but also on the areas of the body where fat is stored ...

What happens when this doctor goes keto and his LDL rockets to 574? We dive deep into the science, controversy, and personal decision-making behind the most misunderstood lipid profile in cardiology.

A recent medical study has revealed that individuals struggling with obesity and high blood pressure face significantly ...

Swiss pharmaceutical manufacturer Roche reports phase 2 results for CT-388, pointing to possible expansion in the fast-growing weight-loss market ...